Title:
CONJUGATES OF FERRITES AND OLIGONUCLEOTIDES, WHICH BOND SPECIFICALLY TO CERTAIN TARGET STRUCTURES
Document Type and Number:
WIPO Patent Application WO1996040273
Kind Code:
A3
Abstract:
This invention relates to new oligonucleotide conjugates, which contain a coated chemically modified ferrite as signal-transmitting group, on which oligonucleotides are bound by connecting components. In this case, the oligonucleotides are modified in a way that prevents or at least significantly inhibits the degradation by naturally occurring nucleases. The oligonucleotide can bond specifically and with high bonding affinity on target structures and can thus have a specific diagnostic and/or therapeutic effect on the ferrite.
Inventors:
PFEFFERER DETLEV
KRESSE MAYK
PLATZEK JOHANNES
NIEDBALLA ULRICH
GRIES HEINZ
RADUECHEL BERND
GOLD LARRY
KRESSE MAYK
PLATZEK JOHANNES
NIEDBALLA ULRICH
GRIES HEINZ
RADUECHEL BERND
GOLD LARRY
Application Number:
PCT/EP1996/002442
Publication Date:
March 27, 1997
Filing Date:
June 05, 1996
Export Citation:
Assignee:
SCHERING AG (DE)
NEXSTAR PHARMACEUTICALS INC (DE)
NEXSTAR PHARMACEUTICALS INC (DE)
International Classes:
C07H21/00; A61K31/70; A61K49/00; A61K49/18; A61K51/00; A61K51/12; C07F15/02; C07F19/00; (IPC1-7): A61K49/00; A61K51/04
Domestic Patent References:
| WO1986005815A1 | 1986-10-09 | |||
| WO1993023570A1 | 1993-11-25 | |||
| WO1994001448A1 | 1994-01-20 | |||
| WO1996002669A1 | 1996-02-01 |
Foreign References:
| US5160725A | 1992-11-03 | |||
| EP0295965A2 | 1988-12-21 | |||
| EP0640350A2 | 1995-03-01 | |||
| US5270163A | 1993-12-14 | |||
| DE4424922A1 | 1996-01-18 | |||
| US5516670A | 1996-05-14 |
Other References:
IVERSEN PL ET AL: "Binding of antisense phosphorothioate oligonucleotides to murine lymphocytes is lineage specific and inducible.", ANTISENSE RES DEV, FALL 1992, VOL. 2, NO. 3, PAGE(S) 223-33, XP000615946
PIRRUCCELLO SJ ET AL: "HIV-1 rev antisense phosphorothioate oligonucleotide binding to human mononuclear cells is cell type specific and inducible.", ANTISENSE RES DEV, WINTER 1994, VOL. 4, NO. 4, PAGE(S) 285-9, XP002024861
DEWANJEE MK ET AL: "Development of sensitive radioiodinated anti-sense oligonucleotide probes by conjugation technique.", BIOCONJUG CHEM, JUL-AUG 1991, VOL. 2, NO. 4, PAGE(S) 195-200, XP002024862
TAKAKURA Y. ET AL: "Control of in vivo characteristics of gene and antisense DNA disposition", JPN. J. CANCER CHEMOTHER., 1994, VOL. 21, NO. 3, PAGE(S) 320-324, XP000615980
O'DONOGHUE JA: "Strategies for selective targeting of Auger electron emitters to tumor cells.", J NUCL MED, APR 1996, VOL. 37, NO. 4 SUPPL, PAGE(S) 3S-6S, XP002024863
KAIREMO KJ ET AL: "Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates.", ANTICANCER DRUG DES, SEP 1996, VOL. 11, NO. 6, PAGE(S) 439-49, XP000615940
PIRRUCCELLO SJ ET AL: "HIV-1 rev antisense phosphorothioate oligonucleotide binding to human mononuclear cells is cell type specific and inducible.", ANTISENSE RES DEV, WINTER 1994, VOL. 4, NO. 4, PAGE(S) 285-9, XP002024861
DEWANJEE MK ET AL: "Development of sensitive radioiodinated anti-sense oligonucleotide probes by conjugation technique.", BIOCONJUG CHEM, JUL-AUG 1991, VOL. 2, NO. 4, PAGE(S) 195-200, XP002024862
TAKAKURA Y. ET AL: "Control of in vivo characteristics of gene and antisense DNA disposition", JPN. J. CANCER CHEMOTHER., 1994, VOL. 21, NO. 3, PAGE(S) 320-324, XP000615980
O'DONOGHUE JA: "Strategies for selective targeting of Auger electron emitters to tumor cells.", J NUCL MED, APR 1996, VOL. 37, NO. 4 SUPPL, PAGE(S) 3S-6S, XP002024863
KAIREMO KJ ET AL: "Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates.", ANTICANCER DRUG DES, SEP 1996, VOL. 11, NO. 6, PAGE(S) 439-49, XP000615940
Download PDF:
Previous Patent: AAV TRANSDUCTION OF MYOBLASTS
Next Patent: CHELATING POLYMERS AS CONTRAST AGENTS FOR MEDICAL IMAGING
Next Patent: CHELATING POLYMERS AS CONTRAST AGENTS FOR MEDICAL IMAGING